On the Expert "Market".
Can't buy in the U.S. and can only sell into a market that has zero liquidity. Who wants to sell for peanuts when the pipeline exhibits massive potential and success on past human trial levels and preclinical superiority that comparable assets have been valued at 10s or even 100s of millions? Who wants to acquire shares with so many unknowns and zero communication?
The tide can turn in a blink next week, next month or into next year, so who knows what their strategy is. A headscratcher for sure. It is not logical to last much longer with activites known to be happening in Q4 and with time ticking on by the greater risks are now missed opportunities, stagnant depreciation, upsetting stakeholders, etc, etc all putting this highly prized pipeline and all the efforts achieving success to this point in an uneccesary adverse situation.
Market Data 
Markets 
AI
